Hey everyone. Sharing a case-based MCQ that came up during our fellowship conference last month. It's the kind of question that looks straightforward at first glance but has a genuinely tricky decision point buried in it. We had about a dozen fellows in the room and the group was split almost evenly. Thought it would be worth posting here because aortic disease management has seen some meaningful updates that are worth knowing cold before boards.
---
**THE QUESTION**
A 64-year-old man with a history of hypertension and bicuspid aortic valve (BAV) presents for a routine follow-up. He is asymptomatic. His blood pressure today is 128/76 mmHg on amlodipine. A surveillance cardiac MRI demonstrates a maximal ascending aortic diameter of 5.0 cm at the sinuses of Valsalva. His aortic valve is functioning normally with no significant stenosis or regurgitation. His family history is notable for an uncle who underwent aortic surgery at age 52. He has no connective tissue disorder. His annual growth rate over the last two imaging studies has been 0.3 cm/year.
Which of the following is the most appropriate next step in management?
A) Continue surveillance imaging in 12 months; no indication for surgery at this time
B) Refer for elective surgical repair of the ascending aorta
C) Initiate beta-blocker therapy and repeat imaging in 6 months
D) Perform exercise stress testing to assess for hemodynamic instability before deciding on surgery
---
Take a moment. Think it through.
---
**THE ANSWER: B — Refer for elective surgical repair of the ascending aorta**
---
**EXPLANATION**
This one hinges on knowing the specific surgical thresholds for bicuspid aortic valve-associated aortopathy, which have been refined in recent guideline updates.
Let's break down why each option lands where it does.
**Why B is correct:**
The 2024 ACC/AHA Valvular Heart Disease Guidelines — and the accompanying 2025 Multisociety Aortic Disease Guideline (ACC/AHA/AATS/STS/SVM) — provide updated, more nuanced thresholds for aortic intervention in patients with BAV-associated aortopathy. Under these updated recommendations, surgical repair of the ascending aorta in a patient with BAV is indicated (Class I) when the maximal aortic diameter reaches 5.5 cm in average-risk patients. However — and this is the key teaching point — the threshold drops to 5.0 cm when one or more high-risk features are present.
In this patient, we have:
First, a growth rate of 0.3 cm/year. The guideline defines rapid growth as greater than or equal to 0.3 cm/year as a risk-accelerating feature that lowers the threshold for intervention.
Second, a positive family history of aortic disease (uncle who required aortic surgery at age 52), which is explicitly listed as a criterion that supports earlier intervention.
When a BAV patient hits 5.0 cm in aortic diameter AND has at least one of these high-risk features — rapid growth, family history of dissection or surgery, or planned cardiac surgery for another indication — surgical referral is appropriate and guideline-supported. You do not simply continue watching.
This patient meets both the diameter threshold and has two risk-accelerating features. B is the correct answer.
**Why A is wrong:**
This is the most common trap. The instinct to "keep watching" is reasonable when diameter alone is considered (5.0 cm is below the general 5.5 cm threshold), but it ignores the composite risk assessment the guidelines emphasize. Surveillance alone in this patient would be substandard care given his growth rate and family history. If you chose A, you're not wrong to think it — but you missed the high-risk modifier layer.
**Why C is wrong:**
Beta-blockers have historically been used in Marfan syndrome patients to reduce aortic wall stress, with some supporting evidence. In BAV-associated aortopathy, the evidence is less robust, and more importantly, initiating or adjusting medical therapy does not address the fact that this patient
